Advertisement |
 |
Expand Your Drug Discovery Pipeline — Target Cell Metabolism with Agilent Seahorse XF Analyzers
Discover novel drug targets for oncology, neurodegeneration, diabetes & cardiovascular disease. Begin your search for cell metabolism targets arranged by disease indication & build your pipeline now!
Download the guide book to advance your target identification studies. |  | | |
|
 |
TABLE OF CONTENTS
|
November 2018 Volume 17, Issue 11 |
 | | |
 |  Comment
News and Analysis
Research Highlights
Reviews
Corrigenda
| | | Advertisement | | | |  Do you have a career question?
The Naturejobs podcast features one-on-one Q&As, panel discussions and other exclusive content to help scientists with their careers. Hosted on the Naturejobs blog, the podcast is also available on iTunes and Soundcloud.
Listen today! | | |
| |
| Advertisement |
|
|
|
| |
| Advertisement |
|
| |
|
| |
Comment | |
| |
Impact of the Innovative Medicines Initiative on vaccine development
Philippe Denoel, Patricia Londoño-Hayes, Magda Chlebus & Magdalena Rodriguez de Azero
pp769 - 770 | doi:10.1038/nrd.2018.72
Since its launch a decade ago, the European Innovative Medicines Initiative (IMI), a leading public–private partnership in life sciences, has catalysed scientific breakthroughs and the development of strategies to address complex challenges in various biomedical fields. Here, we discuss the progress of IMI projects related to vaccine research and development.
Full Text | PDF
|
News and Analysis | |
| |
Cancer stem cell pipeline flounders
Ken Garber
pp771 - 773 | doi:10.1038/nrd.2018.157
With clinical failures mounting and companies disinvesting, researchers are revising the cancer stem cell model.
Full Text | PDF
|
'Party drug' turned antidepressant approaches approval
Sara Reardon
pp773 - 775 | doi:10.1038/nrd.2018.187
Johnson & Johnson has submitted its esketamine for regulatory approval, but researchers still don't understand how the fast-acting antidepressant lifts moods.
Full Text | PDF
|
|
| News in Brief |
|
Re-assessing the rule of 5, two decades on
Asher Mullard
p777 | doi:10.1038/nrd.2018.197
Full Text | PDF
|
How much do phase III trials cost?
Asher Mullard
p777 | doi:10.1038/nrd.2018.198
Full Text | PDF
|
FDA approves first drug under new antibacterial and antifungal drug programme
Asher Mullard
p777 | doi:10.1038/nrd.2018.199
Full Text | PDF
|
|
| Biobusiness Briefs |
|
Patent watch: Selective GABAA receptor modulators: intellectual property landscape
Cecilia Martin & Drew Lowery
p778 | doi:10.1038/nrd.2018.179
Full Text | PDF
|
Regulatory watch: FDA new drug approvals in Q3 2018
Lisa Urquhart
p779 | doi:10.1038/nrd.2018.194
Full Text | PDF
|
|
| An Audience With |
|
Martin VanTrieste
pp780 - 781 | doi:10.1038/nrd.2018.193
Martin VanTrieste, CEO of Civica Rx and former chief quality officer for Amgen, discusses how his hospital-backed non-profit generic drug company plans to bring stability to the generic drug market.
Full Text | PDF
|
|
| From the analyst's couch |
|
Trends in the global immuno-oncology landscape
Jun Tang, Laura Pearce, Jill O'Donnell-Tormey & Vanessa M. Hubbard-Lucey
pp783 - 784 | doi:10.1038/nrd.2018.167
This report analyses the dramatic progress in the global immuno-oncology landscape from September 2017 to September 2018.
Full Text | PDF
Collection: Cancer at Nature Research
|
| Advertisement |
|
Focal Point on Kobe
A seismic shift - How Kobe rebuilt itself after a devastating earthquake and turned into a biotechnology hub |  | | |
|
| |
Research Highlights | |
| |
| |
|
 |
Reviews | |
| |
Targeting G protein-coupled receptor signalling by blocking G proteins
Adrian P. Campbell & Alan V. Smrcka
pp789 - 803 | doi:10.1038/nrd.2018.135
Identifying ligands of G protein-coupled receptors (GPCRs) that elicit biased downstream signalling is an established strategy for separating the desired and unwanted effects of these receptors. Campbell and Smrcka describe how inhibiting the downstream G proteins themselves could also be used to bias GPCR signalling, as well as block pathways shared by multiple GPCRs involved in complex diseases, and discuss how the currently available G protein ligands could be optimized to generate therapeutic leads.
Full Text | PDF
|
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin, Rossella Medori, Robert A. Hauser & Olivier Rascol
pp804 - 822 | doi:10.1038/nrd.2018.136
Existing dopaminergic-based therapies for Parkinson disease (PD) are limited by side effects and lack of long-term efficacy. Here, Charvin et al. discuss the challenges facing the development of novel treatments for PD, assess emerging disease-modifying non-dopaminergic therapeutic strategies and highlight novel therapies aimed at managing symptoms of the disease.
Full Text | PDF
|
Regulatory T cells in the treatment of disease
Amir Sharabi, Maria G. Tsokos, Ying Ding, Thomas R. Malek, David Klatzmann et al.
pp823 - 844 | doi:10.1038/nrd.2018.148
Regulatory T cells are important in controlling immune reactions and thus are implicated in autoimmune diseases, transplantation and cancer. In this Review, Tsokos and colleagues discuss how these cells can be harnessed or manipulated for therapeutic use and describe the progress that has been made as well as impending challenges.
Full Text | PDF
|
Corrigendum | |
| |
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs
Delphine Charvin, Rossella Medori, Robert A. Hauser & Olivier Rascol
p844 | doi:10.1038/nrd.2018.184
Full Text | PDF
|
| Advertisement |
|
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.
Click here to sign up. |  | | |
|
| |
| | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | |
|
No comments:
Post a Comment